Her scientific interests lie mostly in Leukemia, Myeloid leukemia, Internal medicine, Oncology and Immunology. Her biological study spans a wide range of topics, including Cancer, Myeloid, Cancer research, Fms-Like Tyrosine Kinase 3 and NPM1. Her Myeloid leukemia research is multidisciplinary, incorporating perspectives in Genetics, Molecular biology, BAALC, Cytogenetics and Core binding factor acute myeloid leukemia.
Her Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Surgery. Her research investigates the connection between Oncology and topics such as Clinical trial that intersect with issues in Decitabine. In her study, European LeukemiaNet is inextricably linked to Intensive care medicine, which falls within the broad field of Acute leukemia.
Her primary areas of investigation include Leukemia, Internal medicine, Myeloid leukemia, Oncology and Immunology. Her Leukemia research is multidisciplinary, relying on both Cancer, Myeloid, Pathology, BAALC and NPM1. Her study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Surgery.
Her research in Myeloid leukemia focuses on subjects like Cytogenetics, which are connected to Karyotype. The various areas that she examines in her Oncology study include Acute promyelocytic leukemia, European LeukemiaNet, Survival analysis and Transplantation. Her Cancer research research includes elements of Haematopoiesis, Gene expression profiling, Mutation, Gene mutation and microRNA.
Clara D. Bloomfield mainly investigates Myeloid leukemia, Internal medicine, Leukemia, Oncology and Cancer research. Clara D. Bloomfield interconnects Myeloid, Gene mutation, Stem cell, NPM1 and Long non-coding RNA in the investigation of issues within Myeloid leukemia. Her Myeloid study incorporates themes from Survival rate, Adult Acute Myeloid Leukemia, Chromosome and Decitabine.
Immunology covers Clara D. Bloomfield research in Leukemia. In her research on the topic of Oncology, Family medicine is strongly related with Clinical trial. Her study looks at the relationship between Cancer research and topics such as Chromosomal translocation, which overlap with Brachial Plexus Neuritis.
Clara D. Bloomfield focuses on Internal medicine, Myeloid leukemia, Leukemia, Myeloid and Oncology. Myeloid leukemia is a subfield of Cancer research that Clara D. Bloomfield tackles. Leukemia is a subfield of Immunology that Clara D. Bloomfield studies.
Her work on Antibody as part of general Immunology study is frequently linked to EGFL7, therefore connecting diverse disciplines of science. Her studies in Myeloid integrate themes in fields like Cancer, Hematopoietic stem cell transplantation, Survival rate, Decitabine and Nonsense mutation. Her Oncology research incorporates elements of Missense mutation, Targeted Mutation, Tyrosine kinase, Adult Acute Myeloid Leukemia and Frameshift mutation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
T. R. Golub;T. R. Golub;D. K. Slonim;P. Tamayo;C. Huard.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber;Attilio Orazi;Robert Hasserjian;Jürgen Thiele.
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.
Nancy Lee Harris;Elaine S. Jaffe;Jacques Diebold;Georges Flandrin.
Journal of Clinical Oncology (1999)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman;Jüergen Thiele;Daniel A. Arber;Richard D. Brunning.
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner.
Journal of Clinical Oncology (2003)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori.
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll.
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns.
Joseph F. Costello;Joseph F. Costello;Michael C. Frühwald;Michael C. Frühwald;Dominic J. Smiraglia;Laura J. Rush.
Nature Genetics (2000)
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Martin S. Tallman;Janet W. Andersen;Charles A. Schiffer;Frederick R. Appelbaum.
The New England Journal of Medicine (1997)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: